Egle Therapeutics is pioneering advancements in immunotherapy by focusing on the modulation of T-regulatory cells (Tregs), which play a crucial role in maintaining immune balance. The company employs a unique strategy of selectively targeting the most immunosuppressive Tregs, effectively "starving" them to restore a robust immune response. This approach is underpinned by decades of academic research, leading to the development of innovative computationally-based IL-2 modified variants and a translational target discovery platform. Egle's technology integrates specific antibody targeting with modified cytokines, allowing for precise manipulation of Tregs to enhance therapeutic outcomes in oncology and autoimmune diseases.

The company is advancing a pipeline of first-in-class immunotherapies, including EGL-001, a Treg-selective anti-CTLA4-IL-2m for oncology, and EGL-003, a non-targeted IL-2 Treg engager for autoimmune conditions. Egle Therapeutics aims to leverage its unique technology platforms to address significant unmet medical needs in these fields, showcasing the potential of its innovative approaches to transform patient care. The leadership team, composed of seasoned experts in immunology and drug development, is committed to driving these therapies from the lab to clinical application, emphasizing the company's dedication to improving patient outcomes through cutting-edge science.

France

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Egle Therapeutics

Company Details